Wuxi Biologics highlighted their highly integrated and scaled platform, allowing for end-to-end research, development and manufacturing of complex biologics like bi- and multispecifics, fueling their expansion plans, said Chris Chen, PhD, CEO at the 44th Annual JP Morgan Healthcare Conference on 14 January 2026.
Presenting at the conference, Dr Chen discussed their highly integrated and holistic CDRMO+ platform, which allows them to provide all services across the developmental lifecycle of biologic products from preclinical to approved product manufacturing, with Dr Chen stating that Wuxi Biologics is “basically a one-stop shop …with huge scale”. This platform has allowed them to support over 600+ INDs over the last five years, all the while maintaining an impressive 100% success rate across regulatory inspections.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Dr Chen further highlighted their investment as an early adopter of novel modalities and biologic platforms, with Wuxi Biologics being able to now reap the significant benefits of their prescient early movements. Focusing particularly on their CD3 T-Cell Engager (TCE) platform, which was an early strategic investment in 2016, has yielded $200m to date, with 2025 partnerships representing a potential $4bn milestone.
In addition, their investment into more complex biologics such as bi- and multispecifics, antibody drug conjugates (ADCs) and monoclonal antibodies (mAbs) has led Dr Chen to state that these are the “Three most exciting modalities [in the pharma industry] and we are king in all three”. Wuxi Biologics has one of the industry’s largest and most advanced development portfolios with 789 projects as of the end of December 2025. This is also represented in their finances with bi- and multispecifics, ADCs and mAbs accounting for 20% of their revenue, and with 2/3 of all their new projects being one of these modalities, their focus and growth in this area will continue into 2026.
Alongside their investments into products, they have also expanded their manufacturing capacity, with significant investments in their United States facilities, providing an integrated biologics manufacturing system where manufacturing is covered end-to-end. To complement their investment in the US, they have also continued to expand their Asian facilities, outside of China, with their new 120,000L mAb manufacturing hub in Singapore being completed in June of last year in only 15 months. To further complement this, at the end of last year, they committed to develop a facility in Qatar at the end of last year, with Dr Chen stating he envisions the new facility will be employing over a thousand people in ten years and may be able to replicate China-level economics and execution
Dr Chen, in discussing Wuxi Biologics key differentiators, was quick to highlight their adoption of AI and other digital technologies, stating that “[Wuxi Biologics] will be a beneficiary of AI in a year, because we have the scale”. This has led them to develop a series of AI-driven and linked systems to generate a digital transformation within the company, with systems such as Biofoundry and PatroLab leading the charge, allowing for the monitoring of labs and in-silico process modelling and simulation, respectively.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataConcluding his presentation, Dr Chen highlighted their continued regulatory excellence and bispecifics and multispecifics, ADCs and mAbs pipeline focus will lead to a rapid increase in manufacturing revenues going into 2026, and beyond, backed by their strategic new global facilities.
Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare conference 2026. Sign up here to receive a comprehensive report after the conference.
